文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

印度口服霍乱疫苗引入的项目准备与挑战

Programmatic Preparations and challenges for OCV introduction in India.
PubMed 文献 · Vaccine · 2019-07-12

本文介绍印度霍乱疾病负担及口服霍乱疫苗(OCV)引入规划。国家免疫技术咨询组(NTAGI)霍乱工作组于2016年审查证据,基于其建议,卫生和家庭福利部将决定是否将OCV纳入Universal Immunization Programme(UIP)。

要点

  • NTAGI霍乱工作组2016年审查印度霍乱负担及他国OCV实施证据。
  • OCV引入关键步骤包括选择疫苗剂型、制定接种策略、确保资源与可持续供应、开展引入后评估。

核心结论

  • 基于NTAGI建议,印度卫生和家庭福利部将实施霍乱控制措施并决定是否将OCV纳入UIP。

研究设计与样本

  • 本文为项目规划与挑战介绍,NTAGI霍乱工作组于2016年召开会议审查证据。

主要发现

  • 霍乱主要影响边缘化人群,其获得医疗、安全饮水和改善卫生设施的机会不平等。

关键数值与推荐

  • OCV引入关键步骤包括选择疫苗剂型、制定疫苗 delivery 策略、确保充足资源、联系OCV制造商确保可持续供应、制定引入后评估策略。

临床怎么用

  • 基于NTAGI推荐,卫生部将实施霍乱控制措施并评估将OCV纳入UIP。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cholera mainly affects the marginalized with inequitable access to care, potable water and improved sanitation. An estimated 411 million people in India are at risk from cholera, with 675,188 cases and 20,256 deaths occurring annually. Given the global elimination plan for cholera by 2030, a multi-stakeholder strategy is required. The National Technical Advisory Group on Immunization (NTAGI) Working Group on Cholera met in 2016 to review the evidence for cholera burden in India and successful oral cholera vaccine (OCV) implementation in other countries. Based on NTAGI's recommendations, the Ministry of Health and Family Welfare will implement cholera control measures and decide on OCV's addition to India's Universal Immunization Programme (UIP). Key steps for OCV introduction will include choosing the vaccine formulation, developing vaccine delivery strategy, ensuring sufficient resources, engaging OCV manufacturers to ensure a sustainable supply, and developing a post-introduction evaluation strategy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Haldar P. Programmatic Preparations and challenges for OCV introduction in India. Vaccine. 2019. PMID: 31307875. doi:10.1016/j.vaccine.2019.06.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。